Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 65

1.

Naturally occurring antibodies that recognize linear epitopes in the amino terminus of the hepatitis C virus E2 protein confer noninterfering, additive neutralization.

Tarr AW, Urbanowicz RA, Jayaraj D, Brown RJ, McKeating JA, Irving WL, Ball JK.

J Virol. 2012 Mar;86(5):2739-49. doi: 10.1128/JVI.06492-11. Epub 2011 Dec 14.

PMID:
22171278
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Mapping a region of hepatitis C virus E2 that is responsible for escape from neutralizing antibodies and a core CD81-binding region that does not tolerate neutralization escape mutations.

Keck ZY, Saha A, Xia J, Wang Y, Lau P, Krey T, Rey FA, Foung SK.

J Virol. 2011 Oct;85(20):10451-63. doi: 10.1128/JVI.05259-11. Epub 2011 Aug 3.

PMID:
21813602
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

A genetically humanized mouse model for hepatitis C virus infection.

Dorner M, Horwitz JA, Robbins JB, Barry WT, Feng Q, Mu K, Jones CT, Schoggins JW, Catanese MT, Burton DR, Law M, Rice CM, Ploss A.

Nature. 2011 Jun 8;474(7350):208-11. doi: 10.1038/nature10168.

PMID:
21654804
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

In vivo evaluation of the cross-genotype neutralizing activity of polyclonal antibodies against hepatitis C virus.

Meuleman P, Bukh J, Verhoye L, Farhoudi A, Vanwolleghem T, Wang RY, Desombere I, Alter H, Purcell RH, Leroux-Roels G.

Hepatology. 2011 Mar;53(3):755-62. doi: 10.1002/hep.24171. Epub 2011 Feb 11.

PMID:
21319203
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

The results of Phase III clinical trials with telaprevir and boceprevir presented at the Liver Meeting 2010: a new standard of care for hepatitis C virus genotype 1 infection, but with issues still pending.

Pawlotsky JM.

Gastroenterology. 2011 Mar;140(3):746-54. doi: 10.1053/j.gastro.2011.01.028. Epub 2011 Jan 18. No abstract available. Erratum in: Gastroenterology. 2011 Aug;141(2):778.

PMID:
21255572
[PubMed - indexed for MEDLINE]
6.

Hypervariable region 1 differentially impacts viability of hepatitis C virus strains of genotypes 1 to 6 and impairs virus neutralization.

Prentoe J, Jensen TB, Meuleman P, Serre SB, Scheel TK, Leroux-Roels G, Gottwein JM, Bukh J.

J Virol. 2011 Mar;85(5):2224-34. doi: 10.1128/JVI.01594-10. Epub 2010 Dec 1.

PMID:
21123377
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Role of N-linked glycans in the functions of hepatitis C virus envelope proteins incorporated into infectious virions.

Helle F, Vieyres G, Elkrief L, Popescu CI, Wychowski C, Descamps V, Castelain S, Roingeard P, Duverlie G, Dubuisson J.

J Virol. 2010 Nov;84(22):11905-15. doi: 10.1128/JVI.01548-10. Epub 2010 Sep 15.

PMID:
20844034
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Novel infectious cDNA clones of hepatitis C virus genotype 3a (strain S52) and 4a (strain ED43): genetic analyses and in vivo pathogenesis studies.

Gottwein JM, Scheel TK, Callendret B, Li YP, Eccleston HB, Engle RE, Govindarajan S, Satterfield W, Purcell RH, Walker CM, Bukh J.

J Virol. 2010 May;84(10):5277-93. doi: 10.1128/JVI.02667-09. Epub 2010 Mar 3.

PMID:
20200247
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

The disulfide bonds in glycoprotein E2 of hepatitis C virus reveal the tertiary organization of the molecule.

Krey T, d'Alayer J, Kikuti CM, Saulnier A, Damier-Piolle L, Petitpas I, Johansson DX, Tawar RG, Baron B, Robert B, England P, Persson MA, Martin A, Rey FA.

PLoS Pathog. 2010 Feb 19;6(2):e1000762. doi: 10.1371/journal.ppat.1000762.

PMID:
20174556
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

Identification and characterization of broadly neutralizing human monoclonal antibodies directed against the E2 envelope glycoprotein of hepatitis C virus.

Broering TJ, Garrity KA, Boatright NK, Sloan SE, Sandor F, Thomas WD Jr, Szabo G, Finberg RW, Ambrosino DM, Babcock GJ.

J Virol. 2009 Dec;83(23):12473-82. doi: 10.1128/JVI.01138-09. Epub 2009 Sep 16.

PMID:
19759151
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Depletion of interfering antibodies in chronic hepatitis C patients and vaccinated chimpanzees reveals broad cross-genotype neutralizing activity.

Zhang P, Zhong L, Struble EB, Watanabe H, Kachko A, Mihalik K, Virata-Theimer ML, Alter HJ, Feinstone S, Major M.

Proc Natl Acad Sci U S A. 2009 May 5;106(18):7537-41. doi: 10.1073/pnas.0902749106. Epub 2009 Apr 20.

PMID:
19380744
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Mutations in hepatitis C virus E2 located outside the CD81 binding sites lead to escape from broadly neutralizing antibodies but compromise virus infectivity.

Keck ZY, Li SH, Xia J, von Hahn T, Balfe P, McKeating JA, Witteveldt J, Patel AH, Alter H, Rice CM, Foung SK.

J Virol. 2009 Jun;83(12):6149-60. doi: 10.1128/JVI.00248-09. Epub 2009 Mar 25.

PMID:
19321602
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

Rapid generation of fully human monoclonal antibodies specific to a vaccinating antigen.

Smith K, Garman L, Wrammert J, Zheng NY, Capra JD, Ahmed R, Wilson PC.

Nat Protoc. 2009;4(3):372-84. doi: 10.1038/nprot.2009.3.

PMID:
19247287
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

Development and characterization of hepatitis C virus genotype 1-7 cell culture systems: role of CD81 and scavenger receptor class B type I and effect of antiviral drugs.

Gottwein JM, Scheel TK, Jensen TB, Lademann JB, Prentoe JC, Knudsen ML, Hoegh AM, Bukh J.

Hepatology. 2009 Feb;49(2):364-77. doi: 10.1002/hep.22673.

PMID:
19148942
[PubMed - indexed for MEDLINE]
15.

In vitro selection of a neutralization-resistant hepatitis C virus escape mutant.

Gal-Tanamy M, Keck ZY, Yi M, McKeating JA, Patel AH, Foung SK, Lemon SM.

Proc Natl Acad Sci U S A. 2008 Dec 9;105(49):19450-5. doi: 10.1073/pnas.0809879105. Epub 2008 Dec 3.

PMID:
19052239
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Highly efficient JFH1-based cell-culture system for hepatitis C virus genotype 5a: failure of homologous neutralizing-antibody treatment to control infection.

Jensen TB, Gottwein JM, Scheel TK, Hoegh AM, Eugen-Olsen J, Bukh J.

J Infect Dis. 2008 Dec 15;198(12):1756-65. doi: 10.1086/593021.

PMID:
19032070
[PubMed - indexed for MEDLINE]
Free Article
17.

Polyclonal immunoglobulins from a chronic hepatitis C virus patient protect human liver-chimeric mice from infection with a homologous hepatitis C virus strain.

Vanwolleghem T, Bukh J, Meuleman P, Desombere I, Meunier JC, Alter H, Purcell RH, Leroux-Roels G.

Hepatology. 2008 Jun;47(6):1846-55. doi: 10.1002/hep.22244.

PMID:
18452146
[PubMed - indexed for MEDLINE]
18.

Definition of a conserved immunodominant domain on hepatitis C virus E2 glycoprotein by neutralizing human monoclonal antibodies.

Keck ZY, Li TK, Xia J, Gal-Tanamy M, Olson O, Li SH, Patel AH, Ball JK, Lemon SM, Foung SK.

J Virol. 2008 Jun;82(12):6061-6. doi: 10.1128/JVI.02475-07. Epub 2008 Apr 9.

PMID:
18400849
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

A point mutation leading to hepatitis C virus escape from neutralization by a monoclonal antibody to a conserved conformational epitope.

Keck ZY, Olson O, Gal-Tanamy M, Xia J, Patel AH, Dreux M, Cosset FL, Lemon SM, Foung SK.

J Virol. 2008 Jun;82(12):6067-72. doi: 10.1128/JVI.00252-08. Epub 2008 Apr 2.

PMID:
18385242
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

Dissecting the role of putative CD81 binding regions of E2 in mediating HCV entry: putative CD81 binding region 1 is not involved in CD81 binding.

Rothwangl KB, Manicassamy B, Uprichard SL, Rong L.

Virol J. 2008 Mar 20;5:46. doi: 10.1186/1743-422X-5-46.

PMID:
18355410
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk